TAG:
laboratories
Florida Issues State RFP For Sole Medicaid Lab
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
CEO SUMMARY: If competitive bidding for Medicare business is something universally viewed as bad by the laboratory industry, then the lab services RFP issued by Florida’s Medicaid program must be considered a serious threat to the status quo. Further, the fact that Medicaid officials in…
LabCorp Buys MDS Labs In New York and Georgia
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
CEO SUMMARY: It’s the final chapter of the “Canadian Invasion” of the U.S. laboratory testing market. In the mid-1990s, both MDS and Dynacare built a sizeable presence in the United States as they both worked to develop joint ventures with hospital laboratories. Dynacare was acquire…
Seattle Hospital Lab JVs Involve Quest & LabCorp
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
CEO SUMMARY: Joint ventures and collaborative business relationships between hospital laboratories and commercial laboratories continue to be a difficult business model. Recent events in Seattle demonstrate the challenges and frustrations of establishing such ventures, then making them su…
AmeriPath Reports on 2003, Its First Year as a Private Firm
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
WILL BUSINESS BE BETTER for AmeriPath, Inc. as a private company than it was as a publicly-traded firm? Its 2003 financial report indicates some interesting challenges, many common to all laboratories. First, a look at basic numbers. AmeriPath’s net revenues grew from $478.8 milli…
“April 5, 2004 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
There’s a new national lab company ready to compete. This week American Esoterix Laboratories, Inc. (AEL) announced it was open and ready for business. Based in Brentwood, Tennessee, it has already completed two lab acquisitions (ThromboCare Laboratories and …
Oncology Diagnostics Attracts Big Money
By R. Lewis Dark | From the Volume XI No. 4 – March 15, 2004 Issue
MORE SURPRISING DEVELOPMENTS for the anatomic pathology profession during the past three weeks! The impending $215 million acquisition of IMPATH, Inc. by Genzyme Corporation, announced on March 1, has the …
IMPATH Has a Buyer: Genzyme Pays $215 Mil
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
HCA, Tenet Healthcare, CMS, Abbott Labs, I-Stat, TheraSense
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
UNINSURED PATIENT HOSPITAL CHARGES REDUCED AT HCA & TENET For-profit hospital ompanies moved swiftly to announce and publicize new policies for billing uninsured patients. These patients will see charges reduced to levels that are closer to what hospitals accept from HMOs and Medicare/Me…
Side-by-Side Comparison: U.S. Lab Versus British Lab
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: Do clinical laboratories in any of the world’s most developed countries have a performance advantage that makes them “best of breed?” Recently, a laboratory in the United States and a laboratory in the United Kingdom had the opportunity to evaluate their financial, prod…
Public Labs’ Year-End Earnings Demonstrate Continued Growth
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
BECAUSE OF ACQUISITIONS, there remain only four public laboratory companies which do substantial business in testing referred by physicians’ offices. As public companies, their quarterly financial reports provide useful insights into the competitive marketplace for lab testing services. That is t…
CURRENT ISSUE

Volume XXXII, No. 10 – July 14, 2025
This issue is strong on different flavors of enforcement that clinical laboratories, whether they want to or not, will need to contend with. Lab stakeholders provide insights that medical labs need to brace for more action to counter pending test reimbursement rate cuts under PAMA. Also, this issue provides the legal and regulatory landscape for clinical labs’ use of AI and how it evolves with the technology. AI is creating legal uncertainty for clinical labs, especially around data privacy and FDA oversight of AI tools in diagnostics.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized